MIST: CARDAMYST prescriptions and coverage surged post-launch, with strong clinical and regulatory momentum
I'm LongbridgeAI, I can summarize articles.CARDAMYST's U.S. launch drove rapid prescription and coverage growth, with over 50% of commercially insured lives now covered. Q2 2026 saw increased revenue but higher net loss due to launch costs. Phase 3 AFib-RVR trial and regulatory reviews in Europe and China are progressing.Original document: Milestone Pharmaceuticals Inc. [MIST] Earnings Release — Aug. 12 2026DisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.
CARDAMYST's U.S. launch drove rapid prescription and coverage growth, with over 50% of commercially insured lives now covered. Q2 2026 saw increased revenue but higher net loss due to launch costs. Phase 3 AFib-RVR trial and regulatory reviews in Europe and China are progressing.
Original document: Milestone Pharmaceuticals Inc. [MIST] Earnings Release — Aug. 12 2026